Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения

Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения

Автор: Каштанов Максим Геннадьевич, Чернышев С.Д., Кардапольцев Л.В., Бердников С.В., Идов Э.М.

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Рубрика: Обзоры

Статья в выпуске: 1 т.21, 2017 года.

Бесплатный доступ

В статье рассмотрены вопросы отбора больных для этаноловой септальной аблации при обструктивной гипертрофической кардиомиопатии на основе мирового опыта и данных литературы. С точки зрения доказательной медицины освещен метод этаноловой септальной аблации в комплексном лечении пациентов с гипертрофической кардиомиопатией.

Гипертрофическая кардиомиопатия, обструкция выходного тракта левого желудочка, отбор пациентов, этаноловая септальная аблация

Короткий адрес: https://sciup.org/142140775

IDR: 142140775   |   DOI: 10.21688-1681

Список литературы Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения

  • Sorajja P., Ommen S.R., Holmes D.R. Jr., Dearani J.A., Rihal C.S., Gersh B.J., Lennon R.J., Nishimura R.A. 2012 Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circufation. 2012;126(20):2374-80. https://doi.org/10.1161/CIRCULATIONAHA.111.076257
  • Veselka J., Krejc J., Tomasov P., Zemanek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35(30):2040-5. https://doi.org/10.1093/eurheartj/eht495
  • Vriesendorp P.A., Liebregts M., Steggerda R.C., Schinkel A.F., Willems R., Ten Cate F.J., van Cleemput J., Ten Berg J.M., Michels M. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Faif. 2014;2(6):630-6. https://doi.org/10.1016/j. jchf.2014.06.012
  • Yang Y.J., Fan C.M., Yuan J.Q., Qiao S.B., Hu F.H., Guo X.Y., Li Y.S. Survival after alcohol septal ablation versus conservative therapy in obstructive hypertrophic cardiomyopathy. Cardiof J. 2015;22(6):657-64. https://doi.org/10.5603/CJ.a2015.0032
  • Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., McKenna W.J.,Mogensen J., Nihoyannopoulos P., Nistri S., Pieper P.G.,Pieske B., Rapezzi C., Rutten F.H., Tillmanns C., Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. https://doi.org/10.1093/eurheartj/ehu284
  • Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E. and Yancy C.W. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circufation. 2011;124(24):e783-e831. https://doi.org/10.1161/CIR.0b013e318223e230
  • Maron B.J., Gottdiener J.S., Epstein S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48(3):418-28.
  • Cooper R.M., Shahzad A., Stables R.H. Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation. Echo Res Pract. 2015;2(1):R25-R35. https://doi.org/10.1530/ERP-14-0058
  • Kitamura M., Amano Y., Takayama M., Shibuya J., Matsuda J., Sangen H., Nakamura S., Takano H., Asai K., Shimizu W. Abstract 16703: extended non-anteroseptal region left ventricular hypertrophy predicts repeat alcohol septal ablation for refractory hypertrophic obstructive cardiomyopathy: morphological investigation using cardiac magnetic resonance. Circulation. 2015;132(3):A16703.
  • Lu M., Du H., Gao Z., Song L., Cheng H., Zhang Y., Yin G., Chen X., Ling J., Jiang Y., Wang H., Li J., Huang J., He Z., Zhao S. Predictors of outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: an echocardiography and cardiovascular magnetic resonance imaging study. Circ Cardiovasc Interv. 2016;9(3):e002675. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002675
  • Cecchi F., Olivotto I., Nistri S., Antoniucci D., Yacoub M.H. Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy. Herz. 2006;31(9):871 6. https://doi.org/10.1007/s00059-006-2928-1
  • Sorajja P., Binder J., Nishimura R.A., Holmes D.R. Jr., Rihal C.S., Gersh B.J., Bresnahan J.F., Ommen S.R. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2013;81(1):E58-67. https://doi.org/10.1002/ccd.24328
  • Jensen M.K., Jacobsson L., Almaas V., van Buuren F., Hansen P.R., Hansen T.F., Aakhus S., Eriksson M.J., Bundgaard H., Faber L. Influence of septal thickness on the clinical outcome after alcohol septal alation in hypertrophic cardiomyopathy. Circ Cardiovasc Interv. 2016;9(6). https://doi.org/10.1161/CIRCINTERVENTIONS.115.003214
  • Jensen M.K., Almaas V.M., Jacobsson L., Hansen P.R., Havndrup O., Aakhus S., Svane B., Hansen T.F., Kober L., Endresen K., Eriksson M.J., Jorgensen E., Amlie J.P., Gadler F., Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Circ Cardiovasc Interv. 2011;4(3):256-65. https://doi.org/10.1161/CIRCINTERVENTIONS.110.959718
  • Fernandes V.L., Nielsen C., Nagueh S.F., Herrin A.E., Slifka C., Franklin J., Spencer W.H. 3rd. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008;1(5):561-70. https://doi.org/10.1016/j.jcin.2008.07.005
  • Veselka J., Jensen M.K., Liebregts M., Januska J., Krejci J., Bartel T., Dabrowski M., Hansen P.R., Almaas V.M., Seggewiss H., Horstkotte D., Tomasov P., Adlova R., Bundgaard H., Steggerda R., Ten Berg J., Faber L. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur HeartJ. 2016;37(19):1517 23. https://doi.org/10.1093/eurheartj/ehv693
  • Patel P., Dhillon A., Popovic Z.B., Smedira N.G., Rizzo J., Thamilarasan M., Agler D., Lytle B.W., Lever H.M., Desai M.Y. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132. https://doi. org/10.1161/CIRCIMAGING.115.003132
  • Schäfer U., Kreidel F., Frerker C. MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ. 2014;23(5):e131-5. https://doi. org/10.1016/j.hlc.2014.01.007
  • Cavalcante J.L., Barboza J.S., Lever H.M. 2012 Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy. Progress in Cardiovascular Diseases. 2012;54(6):517-22. https://doi. org/10.1016/j.pcad.2012.03.002
  • Cardim N., Galderisi M., Edvardsen T., Plein S., Popescu B.A., D'Andrea A., Bruder O., Cosyns B., Davin L., Donal E., Freitas A., Habib G., Kitsiou A., Petersen S.E., Schroeder S., Lancellotti P., Camici P., Dulgheru R., Hagendorff A., Lombardi M., Muraru D., Sicari R. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. EHJ -Cardiovascular Imaging. 2015;16(3):280. https://doi.org/10.1093/ehjci/jeu291
  • Kwon D.H., Setser R.M., Thamilarasan M., Popovic Z.V., Smedira N.G., Schoenhagen P., Garcia M.J., Lever H.M., Desai M.Y. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart. 2008;94(10):1295-1301. https://doi.org/10.1136/hrt.2007.118018
  • Kwon D.H., Smedira N.G., Thamilarasan M., Lytle B.W., Lever H., Desai M.Y. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg. 2010;140(2):317 24. https://doi.org/10.1016/j.jtcvs.2009.10.045
  • Silbiger J.J. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights. J Am Soc Echocardiogr. 2016;29(7):622-39. https://doi.org/10.1016/j.echo.2016.03.003
  • Halpern D.G., Swistel D.G., Po J.R., Joshi R., Winson G., Arabadjian M., Lopresto C., Kushner J., Kim B., Balaram S.K., Sherrid M.V. Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2015;28(11):1318-28. https://doi.org/10.1016/j.echo.2015.07.002
  • Sherrid M.V., Balaram S., Kim B., Axel L., Swistel D.G. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J Am Coll Cardiol. 2016;67(15):1846-58. https://doi. org/10.1016/j.jacc.2016.01.071
  • Klues H.G., Proschan M.A., Dollar A.L., Spirito P., Roberts W.C., Maron B.J. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. Circulation. 1993;88(2):548-55.
  • Ro R., Halpern D., Sahn D.J., Homel P., Arabadjian M., Lopresto C., Sherrid M.V. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol. 2014;64(19):1984-95. https://doi.org/10.1016/j.jacc.2014.04.090
  • Kim D.-H., Handschumacher M.D., Levine R.A., Choi Y.-S., Kim Y.J., Yun S.-C., Song J.-M., Kang D.-H., Song J.-K. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation. 2010;122(13):1298-1307. http://doi.org/10.1161/ href='contents.asp?titleid=14507' title='Circulation'>CirculationAHA.109.935551
  • van der Lee C., ten Cate F.J., Geleijnse M.L., Kofflard M.J., Pedone C., van Herwerden L.A., Biagini E., Vletter W.B., Serruys P.W. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circufation. 2005;112(4):482-8. http://doi.org/10.1161/CIRCULATIONAHA.104.508309
  • Swistel D.G., Balaram S.K. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the "RPR" repair: resection, plication, and release. Prog Cardiovasc Dis. 2012;54(6):498-502. http://doi.org/10.1016/j.pcad.2012.03.001
  • Maron B.J., Harding A.M., Spirito P., Roberts W.C., Waller B.F. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circufation. 1983;68(2):282-93.
  • Maron M.S., Olivotto I., Harrigan C., Appelbaum E., Gibson C.M., Lesser J.R., Haas T.S., Udelson J.E., Manning W.J., Maron B.J. Mitral valve abnormalities identified bycardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circufation. 2011;124(1):40-7. http://doi.org/10.1161/CIRCULATIONAHA.110.985812
  • Klues H.G., Roberts W.C., Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circufation. 1991;84:1188-97. https://doi.org/10.1161/01.CIR.84.3.1188
  • Minakata K., Dearani J.A., Nishimura R.A., Maron B.J., Danielson G.K. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004127(2):481-9. https://doi.org/10.1016/j.jtcvs.2003.09.040
  • Levine R.A., Vlahakes G.J., Lefebvre X., Guerrero J.L., Cape E.G., Yoganathan A.P., Weyman A.E. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circufation. 1995;91(4):1189-95.
  • Ferrazzi P., Spirito P., Iacovoni A., Calabrese A., Migliorati K., Simon C., Pentiricci S., Poggio D., Grillo M., Amigoni P., Iascone M., Mortara A., Maron BJ., Senni M., Bruzzi P. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J Am Coff Cardiof. 2015;66(15):1687-96. https://doi.org/10.1016/j.jacc.2015.07.069
  • Bogachev-Prokophiev A., Zheleznev S., Fomenko M., Pivkin A., Afanasiev A., Sharifulin R., Karaskov A. Mitral Subvalvular Apparatus Intervention In Patients With Obstructive Hypertrophic Cardiomyopathy: does it need? J Cardiothorac Surg. 2015;10(1):A138. https://doi.org/10.1186/1749-8090-10-S1-A138
  • Talreja D.R., Nishimura R.A., Edwards W.D., Valeti U.S., Ommen S.R., Tajik A.J., Dearani J.A., Schaff H.V., Holmes D.R. Jr. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coff Cardiof. 2004;44(12):2329-32. https://doi.org/10.1016/j. jacc.2004.09.036
  • Кретов Е.И. Непосредственные результаты транскоронарной септальной аблации у больных с гипертрофической обструктивной кардиомиопатией: дис. канд. мед. наук. Новосибирс, 2011. 88 с.
  • Stouffer G., editor. Cardiovascular Hemodynamics for the Clinician. John Wiley and Sons; 2007. 314 p.
  • Караськов А.М., Осиев А.Г. Гипертрофическая кардиомиопатия с обструкцией выходного отдела левого желудочка. Новосибирск, 2012. 187 с.
  • Maron B.J., Yacoub M., Dearani J.A. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J. 2011;32(9):1055-8. https://doi. org/10.1093/eurheartj/ehr006
  • Nagueh S.F., Groves B.M., Schwartz L., Smith K.M., Wang A., Bach R.G., Nielsen C., Leya F., Buergler J.M., Rowe S.K., Woo A., Maldonado Y.M., Spencer W.H. 3rd. 2011 Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy a multicenter North American registry. J Am Coff Cardiof. 2011;58(22):2322-8. https://doi.org/10.1016/j.jacc.2011.06.073
  • Agarwal S., Tuzcu E.M., Desai M.Y., Smedira N., Lever H.M., Lytle B.W., Kapadia S.R. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coff Cardiof. 2010;55(8):823-34. https://doi.org/10.1016/j. jacc.2009.09.047
  • Liebregts M., Vriesendorp P.A., Mahmoodi B.K., Schinkel A.F., Michels M., ten Berg J.M. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Faif. 2015;3(11):896-905. https://doi.org/10.1016/j.jchf.2015.06.011
  • Singh K., Qutub M., Carson K., Hibbert B., Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc/nterv. 2016;88(1):107-15. https://doi. org/10.1002/ccd.26293
  • Ralph-Edwards A., Woo A., McCrindle B.W., Shapero J.L., Schwartz L., Rakowski H., Wigle E.D., Williams W.G. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129(2):351-8. https://doi. org/10.1016/j.jtcvs.2004.08.047
  • Sorajja P., Valeti U., Nishimura R.A., Ommen S.R., Rihal C.S., Gersh B.J., Hodge D.O., Schaff H.V., Holmes D.R. Jr. Outcome of alcohol septal ablation for obstructive hypertrophic Cardiomyopathy. Circufation. 2008;118(2):131-9. https://doi. org/10.1161/CIRCULATIONAHA.107.738740
  • Sedehi D., Finocchiaro G., Tibayan Y., Chi J., Pavlovic A., Kim Y.M., Tibayan F.A., Reitz B.A., Robbins R.C., Woo R.H., Lee D.P., Ashley E.A. Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy. Journal of Cardiology. 2015;66(1):57-62. https://doi.org/10.1016/j.jjcc.2014.08.010
  • Panaich S.S., Badheka A.O., Chothani A., Mehta K., Patel N.J., Deshmukh A., Singh V., Savani G.T., Arora S., Patel N., Bhalara V., Grover P., Shah N., Elder M., Mohamad T., Kaki A., Kondur A., Brown M., Grines C., Schreiber T. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from nationwide inpatient sample ). Am J Cardiof. 2014;114(9):1390-5. https://doi.org/10.1016/j.amjcard.2014.07.075
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp